Albany Molecular Research (AMRI) – StreetInsider.com Reports
-
Paulson's 13F Shows New Stake in Calpine (CPN), EQT (EQT), Sprint (S), Reduced Teva (TEVA), Exits Facebook (FB), AIG (AIG) (More...)
-
Albany Molecular Research (AMRI) Reports Completion of Acquisition by The Carlyle Group, GTCR
-
Control4 (CTRL) Set to Join S&P SmallCap 600
-
UPDATE: Paulson's 13F Shows New Hertz (HTZ) Puts, Stake in Horizon Pharma (HZNP), (More...)
-
Albany Molecular Research (AMRI) Reports Early Termination of HSR Waiting Period for Carlyle, GTCR's Proposed Acquisition
-
JPMorgan Downgrades Albany Molecular Research Inc. (AMRI) to Neutral Following Acquisition
-
William Blair Downgrades Albany Molecular (AMRI) to Market Perform Following Acquisition Agreement
-
Options with decreasing implied volatility
-
Pre-Open Movers 06/06: (NIHD) (EGLT) (GIII) Higher; (HDS) (FRAN) (CONN) Lower (more...)
-
Albany Molecular Research (AMRI) to Resume Trading at 8:00 AM ET
-
Albany Molecular Research (AMRI) Agrees to Be Acquired by The Carlyle Group and GTCR for $21.75/Share
-
Albany Molecular Research (AMRI) Halted, News Pending
-
Albany Molecular Research (AMRI) calls active on report PE firms looking to acquire
-
Albany Molecular Research (AMRI) halted LUDP follow new report on sale of the company from Reuters
-
GTCR, Carlyle in Talks to Acquire Albany Molecular Research (AMRI) - Reuters
-
Morgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
-
Albany Molecular Research (AMRI) Tops Q1 EPS by 1c
-
Albany Molecular Research (AMRI) Reports 5-Yr NIH Contract for Drug Substance Development & Manufacturing Svcs
-
UPDATE: Albany Molecular Research (AMRI) Working with Credit Suisse to Explore Sale; Received Interest from Carlyle, Pamplona - Bloomberg
-
Denovo Biopharma Obtains Exclusive License to Liafensine from Albany Molecular Research (AMRI)
-
Albany Molecular Research (AMRI) Climbs on Rumors It's Exploring Sale
-
Albany Molecular Research (AMRI) Files to Offer 2.2M Shares for Holders
-
Albany Molecular Research (AMRI) Misses Q4 EPS by 14c; Guides Below the Street
-
Albany Molecular Research (AMRI) Enters Multi-Year Supply Agreement with Shire
-
Albany Molecular Research (AMRI) Tops Q3 EPS by 4c
-
Trading Radar for 11/8: D. R. Horton (DHI), Valeant Pharma (VRX), CVS Health (CVS), Valvoline (VVV) Report
-
Albany Molecular Research (AMRI) Files 7.05M Common Stock Shelf for Shareholders
-
Albany Molecular Research (AMRI) Announces Euticals Acquisition-Related Restructuring Plan
-
AAMRI (AMRI) Enters License Agreement for CRISPR-Cas9 Gene Editing Technology
-
Albany Molecular Research (AMRI) Tops Q2 EPS by 4c; Updates FY16 Expectations
-
Trading Radar for 8/4: Kellogg (K), MGM Resorts (MGM), Activision (ATVI), FireEye (FEYE), Weight Watchers (WTW) Report
-
Albany Molecular Research (AMRI) Announces Completion of Euticals Acquisition
-
Albany Molecular Research (AMRI) Misses Q1 EPS by 14c
-
Notable Mergers and Acquisitions 5/5: (NFX)/(CHK) (VG) (AMRI) (ZPIN) (RILY)/(UNTD)
-
AMRI (AMRI) to Acquire Euticals $358M Deal
-
Albany Molecular Research (AMRI) Director Veronica Jordan, Ph.D to Retire
-
Albany Molecular Research (AMRI) Tops Q4 EPS by 4c; Guides In-Line
-
Trading Radar for 2/17: Marriott (MAR), NVIDIA (NVDA), Priceline (PCLN), Barrick Gold (ABX), Albemarle (ALB) Report
-
Albany Molecular Research (AMRI) Receives Extension of Key Insourcing Relationship
-
Albany Molecular Research (AMRI), Eagle Pharma (EGRX) Enter Parenteral Drug Products R&D Collaboration
-
Albany Molecular Research (AMRI), Icagen Sign Collaboration Agreement
-
AMRI (AMRI) Acquires Whitehouse Labs in $56M Deal
-
AMRI (AMRI) Debuts New U.S.-Based Integrated Drug Discovery Center
-
Albany Molecular Research (AMRI) Tops Q3 EPS by 1c
-
Trading Radar for 11/5: Disney (DIS), Celgene (CELG), SeaWorld (SEAS), Sprouts (SFM), CyberArk (CYBR) Report
-
Notable Analyst Rating Changes 10/26: (PYPL) (AMRI) (P) Upgraded; (AKS) (AXP) (CYH) Downgraded
-
First Analysis Upgrades Albany Molecular Research (AMRI) to Overweight
-
Albany Molecular Research (AMRI) Enters Amended GE Healthcare Supply Agreement
-
Albany Molecular Research (AMRI) Files $90M Mixed Shelf
-
Albany Molecular Research (AMRI) Updates FY15 Guidance Following Gadea Pharma Acquisition
Back to AMRI Stock Lookup